Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 701–800 of 1,013
Li, Y., Li, L., Guan, Y., Liu, X., Meng, Q., & Guo, Q. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.111 · Cited by 81
Mechanisms underlying the anticancer activities of the angucycline landomycin E
Korynevska, A., Heffeter, P., Matselyukh, B. P., Elbling, L., Micksche, M., Stoika, R. S., & Berger, W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.026 · Cited by 81
A laccase-catalysed one-pot synthesis of aminonaphthoquinones and their anticancer activity
Wellington, K. W., & Kolesnikova, N. I. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.028 · Cited by 91
Alzheimer’s and ABC transporters — new opportunities for diagnostics and treatment
Pahnke, J., Langer, O., & Krohn, M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.001 · Cited by 81
Goler-Baron, V., Sladkevich, I., & Assaraf, Y. G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.033 · Cited by 83
Hofman, J., Malčeková, B., Skarka, A., Novotná, E., & Wsól, V. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.04.027 · Cited by 87
Ding, P.-R., Tiwari, A. K., Ohnuma, S., Lee, J. W. K. K., An, X., Dai, C.-L., Lu, Q.-S., Singh, S., Yang, D., Talele, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019329 · Cited by 83
“Among these transporters, the ABCB1 transporter is the most important mediator of MDR [7,8], and is responsible for chemotherapeutic drug resistance to a variety of drug, including vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes [9].”
BackgroundBar-Zeev, M., Assaraf, Y. G., & Livney, Y. D. (2016) · Oncotarget · doi:10.18632/oncotarget.8019 · Cited by 80
“This ATP-dependent efflux is mediated by transmembrane transporters of the ATP-binding cassette (ABC) superfamily, of which P-glycoprotein (P-gp/ABCB1) is considered the most dominant [11].”
BackgroundChernikov, I. V., Gladkikh, D. V., Meschaninova, M. I., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.011 · Cited by 84
“P-glycoprotein is a transmembrane ATP-dependent pump effluxing a wide spectrum of hydrophobic compounds from cells, including drugs commonly used in tumor therapy.(21) A direct and universal approach to overcoming tumor drug resistance is to block the expression of genes encoding proteins causing the resistance with t…”
BackgroundDeng, Z., Yan, F., Jin, Q., Li, F., Wu, J., Liu, X., & Zheng, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.018 · Cited by 80
Wang, Z., He, Q., Zhao, W., Luo, J., & Gao, W. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.017 · Cited by 81
“Efforts have been made to develop drugs that either inhibit or bypass the P-gp drug efflux system in order to reverse DR and thus restore the sensitivity of DR cells to multiple anticancer agents since the early 1980s [2,3].”
BackgroundModulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin
Li, H., Krstin, S., & Wink, M. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.169 · Cited by 89
Qian, X., Pan, Y., Huang, Q.-Y., Shi, Y., Huang, Q.-Y., Hu, Z., & Xiong, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s191317 · Cited by 86
“128,129 132 This means, if a therapeutic agent fails to kill all the CSCs, the tumor may regrow.”
Mitochondrial targeted strategies and their application for cancer and other diseases treatment
Li, Q., & Huang, Y. (2020) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00481-0 · Cited by 86
“Multidrug resistance (MDR) is the inevitable result of longterm chemotherapy and a major obstacle to clinical treatment (Szakács et al. 2006; Chen et al. 2016).”
BackgroundStructures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism
Yu, Q., Ni, D., Kowal, J., Manolaridis, I., Jackson, S. M., Stahlberg, H., & Locher, K. P. (2021) · Nature Communications · doi:10.1038/s41467-021-24651-2 · Cited by 80
Bauer, F., Kuntner, C., Bankstahl, J. P., Wanek, T., Bankstahl, M., Stanek, J., Mairinger, S., Dörner, B., Löscher, W., Müller, M., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.057 · Cited by 84
Triterpenoids as reversal agents for anticancer drug resistance treatment
Yan, X., Gong, L.-H., Zheng, F.-Y., Cheng, K., Chen, Z., & Shi, Z. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.018 · Cited by 94
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Liang, D., Wang, A.-T., Yang, Z., Liu, Y., & Qi, X. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00129 · Cited by 82
Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
Wen, S.-H., Su, S.-C., Liou, B., Lin, C.-H., & Lee, K. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0625-9 · Cited by 88
Wu, C., Lusvarghi, S., Wang, J.-C., Hsiao, S.-H., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00274 · Cited by 84
“Current molecular pharmacology 2008, 1, (2), 93–105.”
BackgroundInfluentialFingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors
Poongavanam, V., Haider, N., & Ecker, G. F. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.045 · Cited by 79
Huang, X., Xiao, X., Zhang, Y., Talele, T. T., Salim, A. A., Chen, Z., & Capon, R. J. (2014) · Marine Drugs · doi:10.3390/md12073818 · Cited by 79
“Unfortunately, although three generations of P-gp inhibitors have been developed [5], none have proved to be clinically useful.”
BackgroundAcacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells
Punia, R., Raina, K., Agarwal, R., & Singh, R. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182870 · Cited by 79
Bhirde, A. A., Chikkaveeraiah, B. V., Srivatsan, A., Niu, G., Jin, A. J., Kapoor, A., Wang, Z., Patel, S., Patel, V., Gorbach, A. M., et al. (2014) · ACS Nano · doi:10.1021/nn501223q · Cited by 78
Ren, P., Gong, F., Zhang, Y., Jiang, J., & Zhang, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-4150-3 · Cited by 78
“So far, platinumbased chemotherapy is mostly therapeutic strategy for patients who are in advanced stages of NSCLC but are not candidates for surgery resection [3].”
BackgroundRetractedOnafuye, H., Pieper, S., Mulac, D., Cinatl, J. J., Wass, M. N., Langer, K., & Michaelis, M. (2019) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.10.166 · Cited by 83
Hu, X., & Xuan, Y. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.11.007 · Cited by 80
“Since verapamil was identified as the first P-gp inhibitor, 3 generations of P-gp inhibitors have been developed [4,5].”
BackgroundInfluentialWang, H. H., Vo, T. M., Hajar, A., Li, S., Chen, X., Parissenti, A. M., Brindley, D. N., & Wang, Z. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-37 · Cited by 78
“In general, ABCB1 transports large hydrophobic compounds, whereas ABCC1 and ABCG2 transport both hydrophobic drugs and large anionic compounds [15].”
BackgroundKöhler, S. C., & Wiese, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00188 · Cited by 78
Bierman, W. F. W., Scheffer, G. L., Schoonderwoerd, A., Jansen, G., van Agtmael, M. A., Danner, S. A., & Scheper, R. J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq209 · Cited by 78
Huang, Y., Zhang, G., Hu, F., Jin, Y., Zhao, R., & Zhang, D. (2016) · Chemical Science · doi:10.1039/c6sc02395a · Cited by 79
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Bruckmueller, H., & Cascorbi, I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1876661 · Cited by 93
“The compounds transported by ABCC1 include organic anions and phase II metabolic/conjugate products, thus ABCC1 is involved in elimination of drugs including various anti-cancer agents [268].”
BackgroundAntitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells
Lage, H., Duarte, N., Coburger, C., Hilgeroth, A., & Ferreira, M. U. (2009) · Phytomedicine · doi:10.1016/j.phymed.2009.07.009 · Cited by 77
“…including a decreased drug uptake or an increased drug efflux; the perturbed expression of target enzymes or altered target enzymes; the altered metabolism of drugs; the increased repair of drug-induced DNA damage; or a failure to undergo apoptosis (Teodori et al. 2006; Szak acs et al. 2006).”
BackgroundKlotho Sensitizes Human Lung Cancer Cell Line to Cisplatin via PI3k/Akt Pathway
Wang, Y., Chen, L., Huang, G., He, D., He, J., Xu, W. D., Zou, C., Zong, F., Li, Y., Chen, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057391 · Cited by 79
“P-gp was the first discovered human ABC transporter, and was encoded by the MDR1 gene[35].”
BackgroundABCG2/BCRP Expression Modulates d -Luciferin–Based Bioluminescence Imaging
Zhang, Y., Bressler, J. P., Neal, J., Lal, B., Bhang, H.-E. C., Laterra, J., & Pomper, M. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0944 · Cited by 81
“Many CYP3A4 inducers concurrently serve as modulators of MDR pumps ( 33 , 34).”
BackgroundSezer, A. D. (2016) · InTech eBooks · doi:10.5772/60475 · Cited by 81
McCaffrey, G., Staatz, W. D., Sanchez‐Covarrubias, L., Finch, J. D., DeMarco, K., Laracuente, M., Ronaldson, P. T., & Davis, T. P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07831.x · Cited by 83
MicroRNA‐106a induces multidrug resistance in gastric cancer by targeting RUNX3
Zhang, Y., Lu, Q., & Cai, X. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.06.058 · Cited by 77
“Though chemotherapy is the most common treatment for GC, multidrug resistance (MDR) limited the effect of chemotherapy, which is caused by the development of resistance to multiple chemo-therapeutic agents [2].”
BackgroundLin, G., Zhu, W., Yang, L., Wu, J., Lin, B., Xu, Y., Cheng, Z., Xia, C., Gong, Q., Song, B., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.07.049 · Cited by 78
“because of some unwanted side effects and unpredictable pharmacokinetic interactions with anticancer drugs [2,4].”
BackgroundWang, B., Ma, L., Wang, J., Lei, Z., Gupta, P., Zhao, Y., Li, Z., Liu, Y., Zhang, X., Li, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00335 · Cited by 76
Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp
Zhang, Y., Laterra, J., & Pomper, M. G. (2009) · Neoplasia · doi:10.1593/neo.81264 · Cited by 76
“Verapamil, a potent Pgp inhibitor that does not inhibit ABCG2 [8], had no effect.”
BackgroundMethodInfluentialThe Pharmacological and Physiological Role of Multidrug-Resistant Protein 4
Wen, J., Luo, J., Huang, W., Tang, J., Zhou, H., & Zhang, W. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225656 · Cited by 81
“Early clinical trials using inhibitors of P-glycoprotein are in support of the need for selective inhibitors of target transporters (Szakács et al., 2006).”
BackgroundKu, J. M., Kim, S. R., Hong, S. H., Choi, H., Seo, H. S., Shin, Y. C., & Ko, S. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2509-9 · Cited by 80
“Therefore, doxorubicin is a very important part of a breast cancer therapy regimen and is a generally used agent [4, 5].”
BackgroundDuarte, N., Varga, A., Черепнев, Г. В., Radics, R., Molnar, J. A., & Ferreira, M. U. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.028 · Cited by 76
Mijatovic, T., & Kiss, R. (2013) · Planta Medica · doi:10.1055/s-0032-1328243 · Cited by 81
“…agents are (a) over-expression of members of three ATP-binding cassette (ABC) transporter sub-families, ABCB, ABCC, and ABCG, (b) lung re-sistance-related protein (LRP, identified as the major vault protein (MVP)), and (c) loss of genes, such as p53, that control DNA integrity [5 – 7].”
BackgroundKanagasabai, R., Krishnamurthy, K., Druhan, L. J., & Ilangovan, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.249102 · Cited by 76
Oguri, T., Ozasa, H., Uemura, T., Bessho, Y., Miyazaki, M., Maeno, K., 前田, 浩., Sato, S., & Ueda, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2088 · Cited by 76
“ABCC family members can be subdivided into two groups: (a) ABCC1-3, ABCC6, and ABCC10, which contain 17 transmembrane segments, and (b) ABCC4, ABCC5, ABCC11, and ABCC12, which lack one of the transmembrane regions and have only 12 transmembrane segments (3, 4).”
BackgroundDiterpenes and Their Derivatives as Potential Anticancer Agents
Islam, M. T. (2017) · Phytotherapy Research · doi:10.1002/ptr.5800 · Cited by 84
“The overexpression of adenosine triphosphate binding cassette (ABC) transporters is known for MDR and failure of cancer chemotherapy (Szak acs et al., 2006).”
BackgroundMitochondrion-Targeting Peptides and Peptidomimetics: Recent Progress and Design Principles
Kim, S., Nam, H. Y., Lee, J., & Seo, J. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b00857 · Cited by 75
Hashimoto, N., Tsunedomi, R., Yoshimura, K., Watanabe, Y., Hazama, S., & Oka, M. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-722 · Cited by 81
“One well-known mechanism of chemoresistance is up-regulation of ABC transporters, which mediate efflux of the anti-cancer drugs [37-39]; expression of one ABC transporter, ABCG2, was up-regulated in SK-sphere cells (Figure 8).”
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Nallasamy, P., Chava, S. P., Verma, S. S., Mishra, S., Gorantla, S., Coulter, D. W., Byrareddy, S. N., Batra, S. K., Gupta, S. C., & Challagundla, K. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.009 · Cited by 83
Porphyrin–Gold Nanomaterial for Efficient Drug Delivery to Cancerous Cells
Bera, K., Maiti, S., Maity, M., Mandal, C., & Maiti, N. C. (2018) · ACS Omega · doi:10.1021/acsomega.8b00419 · Cited by 82
Chen, G., Huang, B. X., & Guo, M. (2018) · Phytochemical Analysis · doi:10.1002/pca.2769 · Cited by 77
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
Liu, J., Zhang, K., Cheng, L., Zhu, H., & Xu, T. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s237393 · Cited by 103
“Ivermectin Is a P-Glycoprotein (P-Gp) Inhibitor Based on the phenomenon of multidrug resistance (MDR), cancer cells can develop resistance and cross-resistance to a variety of chemotherapeutic drugs that are not related to their function and structure after exposure to chemotherapeutic agents.(57) Drug resistance is a…”
BackgroundIRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells
Gao, Q., Li, X., Xu, Y., Zhang, J., Rong, S.-D., Qin, Y.-Q., & Fang, J. S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.007 · Cited by 84
Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer
Yang, R., Yi, M., & Xiang, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.875318 · Cited by 86
Chegaev, K. Y., Riganti, C., Lazzarato, L., Rolando, B., Guglielmo, S., Campia, I., Fruttero, R., Bosìa, A., & Gasco, A. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100302t · Cited by 79
Zhou, L., Lv, F., Liu, L., Shen, G., Yan, X., Bazan, G. C., & Wang, S. (2018) · Advanced Materials · doi:10.1002/adma.201704888 · Cited by 81
Xu, P., Jiang, L., Yang, Y., Wu, M., Liu, B., Shi, Y., Shen, Q., Jiang, X., He, Y., Cheng, D., et al. (2020) · Theranostics · doi:10.7150/thno.43142 · Cited by 78
“, activation of multidrug-resistance (MDR)-associated protein transporters, resistance to apoptosis or senescence signaling pathways and altered expression of detoxifying enzymes [6-9].”
BackgroundPleiotropic Roles of ABC Transporters in Breast Cancer
He, J., Fortunati, E., Liu, D., & Li, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063199 · Cited by 83
Zhang, W., Lü, J., Gao, X., Li, P., Zhang, W., Ma, Y., Wang, H., & Tang, B. (2018) · Angewandte Chemie · doi:10.1002/ange.201710800 · Cited by 75
Genetics of basal cell carcinoma
de Zwaan, S. E., & Haass, N. K. (2009) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2009.00579.x · Cited by 87
“Adenosine triphosphate-binding cassette transporters are central both to the blood brain barrier(77) and to multidrug resistance, and inhibition of them may be important in avoiding the chemotherapeutic treatment failure that is common with so many anticancer drugs.(78) Other anticancer drugs that act on ABC transport…”
BackgroundCampa, D., Müller, P., Edler, L., Knoefel, L. F., Barale, R., Heußel, C. P., Thomas, M., Canzian, F., & Risch, A. (2012) · International Journal of Cancer · doi:10.1002/ijc.27567 · Cited by 99
“Some members of this family like ABCB1 (also known as multidrug resistance-1, MDR1), ABCG2 (breast cancer resistance protein, BCRP) or ABCC2 (multidrug resistance-associated protein-2, MRP2) are well known for their role in multidrug resistance.(12) In normal lung, ABCB1 is expressed on the apical surface of bronchial…”
BackgroundNing, F.-L., Wang, F., Li, M.-L., Yu, Z.-S., Hao, Y.-Z., & Chen, S.-S. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-143 · Cited by 74
“However, the development of chemoresistance is a major obstacle limiting successful treatment [2].”
BackgroundClay, A. T., & Sharom, F. J. (2012) · Biochemistry · doi:10.1021/bi301532c · Cited by 76
Tang, J., Ji, H., Ren, J., Li, M., Zheng, N., & Wu, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.5421 · Cited by 74
“It was reported that P-gp function was significantly correlated with Rh 123 efflux, and that inhibition of P-gp could result in increased intracellular accumulation of Rh 123 (29).”
Ma, H., Yuan, L., Li, W., Xu, K., & Yang, L. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26883 · Cited by 76
Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma
Wangari‐Talbot, J., & Hopper-Borge, E. A. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.04.5 · Cited by 89
“ABCB1 transports hydrophobic substrates, lipids, steroids, antibiotics, antihistamines, anticancer drugs such anthracyclines, vinka alkaloids and taxanes [153, 154].”
BackgroundSugano, T., Seike, M., Noro, R., Soeno, C., Chiba, M., Zou, F., Nakamichi, S., Nishijima, N., Matsumoto, M., Miyanaga, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0050 · Cited by 76
“Previous studies reported that increased ABCB1 conferred resistance to chemotherapeutic agents in several cancers (31-33) .”
BackgroundMiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma
Sun, S., Wang, X., Xu, X., Di, H., Du, J., Xu, B., Wang, Q., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13789 · Cited by 78
Elzahabi, H. S. A., Nossier, E. S., Khalifa, N. M., Alasfoury, R. A., & El‐Manawaty, M. A. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437729 · Cited by 78
Bioinstructive microparticles for self-assembly of mesenchymal stem Cell-3D tumor spheroids
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.007 · Cited by 73
“Such unique crosstalk between cancer cells and their TME may lead to a decreased cell cycle arrest, increased repair of DNA damage, reduced apoptosis, and an increase in energy-dependent efflux of hydrophobic chemotherapeutics such as Doxorubicin is also often obtained [84,85].”
BackgroundFibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer
Gong, Z., Chen, M., Ren, Q., Yue, X., & Dai, Z. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0104-3 · Cited by 74
“As the first choice for the treatment of cancers,(6) chemotherapy agents generally suffer low delivery efficiency to the tumor site with significant variation among different patients.(7) That is because of the resistance of metastatic site leading to low-efficiency therapeutic effect exists in cytotoxic agents, which…”
BackgroundRole of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review
Mir, S. A., Hamid, L., Bader, G. N., Shoaib, A., Rahamathulla, M., Alshahrani, M. Y., Alam, P., & Shakeel, F. (2022) · Molecules · doi:10.3390/molecules27196608 · Cited by 78
“These proteins have a significant role in the development of drug resistance [40].”
BackgroundKuete, V., Sandjo, L. P., Mbaveng, A. T., Seukep, A. J., Ngadjui, B. T., & Efferth, T. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0841-y · Cited by 78
“transporters, particularly breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) [1], as well as the epidermal growth factor receptor (EGFR) [2–4]”
BackgroundDörner, B., Kuntner, C., Bankstahl, J. P., Bankstahl, M., Stanek, J., Wanek, T., Stundner, G., Mairinger, S., Löscher, W., Müller, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900940f · Cited by 81
Dittmar, T., Schwitalla, S., Seidel, J., Haverkampf, S., Reith, G., Meyer-Staeckling, S., Brandt, B., Niggemann, B., & Zänker, K. S. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9359-3 · Cited by 75
“ABCC11 (MRP8), whereas resistance to doxorubicin has been linked to the expression of ABCB1 (PGP/MDR1), ABCC1 (MRP1), ABCC2 (MRP2), and ABCG2 (MXR/ BCRP) [46, 47].”
Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein)
Sim, H., Lee, C. Y., Ee, P. L. R., & Go, M. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.07.008 · Cited by 73
miRNA expression patterns in chemoresistant breast cancer tissues
Lv, J., Xia, K., Xu, P., Sun, E., Ma, J., Gao, S., Zhou, Q., Zhang, M., Wang, F., Chen, F., et al. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.09.011 · Cited by 73
Katayama, R., Koike, S., Sato, S., Sugimoto, Y., Tsuruo, T., & Fujita, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01288.x · Cited by 81
The PIM kinases in hematological cancers
Alvarado, Y., Giles, F. J., & Swords, R. T. (2012) · Expert Review of Hematology · doi:10.1586/ehm.11.69 · Cited by 82
Imaging techniques to study drug transporter function in vivo
Tournier, N., Stieger, B., & Langer, O. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.006 · Cited by 79
“elacridar, tariquidar and valspodar) (Szakács et al., 2006) were shown to lead to significant increases in brain distribution of P-gp substrates.”
BackgroundTepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
Wu, Z., Teng, Q., Cai, C., Wang, J., Lei, Z., Yang, Y., Fan, Y., Zhang, J., Li, J., & Chen, Z. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.05.015 · Cited by 73
Li, X., Zhou, S., Abrahams, C. L., Krimm, S., Smith, J., Bajjuri, K. M., Stephenson, H. T., Henningsen, R. A., Hanson, J., Heibeck, T. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0322 · Cited by 77
“P-glycoprotein 1 (P-gp), also known as multidrug resistance protein 1 (MDR1), is an ATP-dependent efflux pump believed to play a key role in the development of drug resistance (19, 20).”
Antibody–Drug Conjugate Payloads
Anderl, J., Faulstich, H., Hechler, T., & Kulke, M. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-541-5_4 · Cited by 72
MicroRNAs and Drug Resistance in Prostate Cancers
Li, F., & Mahato, R. I. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500099g · Cited by 78
Biocompatible Protein Nanocontainers for Controlled Drugs Release
Han, Y., Shchukin, D. G., Yang, J., Simon, C. R., Fuchs, H., & Möhwald, H. (2010) · ACS Nano · doi:10.1021/nn100307j · Cited by 73
“Encapsulating drugs into a biocarrier is also a potential solution for drug resistance by hiding cytotoxic drugs in the carrier.(5) The requirements for a biocarrier include small size, biocompatibility, biodegradability, high loading capacity, and prolonged circulation.”
BackgroundAdvances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Gillet, J.-P., & M. Gottesman, M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163931 · Cited by 72
“These transmembrane proteins are involved in a wide variety of cellular processes in both physiologic and pathologic states [4,5].”
BackgroundMethodSelf-citationBRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
Jaspers, J. E., Sol, W., Kersbergen, A. J., Schlicker, A., Guyader, C., Xu, G., Wessels, L. F. A., Borst, P., Jonkers, J., & Rottenberg, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0839 · Cited by 79
“Brca2;p53 carcinosarcomas can be resensitized to chemotherapy by coadministration of the Pgp inhibitor tariquidar Each drug for which we observed primary resistance in the carcinosarcomas, is known to be transported by drug efflux transporters: olaparib (30), docetaxel (33), and doxorubicin (34) by ABCB1 (also known a…”
BackgroundZhang, Y., Sriraman, S. K., Kenny, H. A., Luther, E., Torchilin, V. P., & Lengyel, E. R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0986 · Cited by 77
“org Mol Cancer Ther; 15(10) October 2016 2287”
BackgroundInfluentialTumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles
Yao, Q., Liu, Y., Kou, L., Tu, Y., Tang, X., & Zhu, L. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.03.012 · Cited by 74
Li, L., Wang, J., Kong, H., Zeng, Y., & Liu, G. (2018) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2018.1528850 · Cited by 71
Zakaria, M. B., Belik, A. А., Liu, C., Hsieh, H., Liao, Y., Malgras, V., Yamauchi, Y., & Wu, K. C. ‐. (2015) · Chemistry - An Asian Journal · doi:10.1002/asia.201500232 · Cited by 74
Ai, Y., Kang, F., Huang, Z., Xue, X., Lai, Y., Peng, S., Tian, J., & Zhang, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5019302 · Cited by 71
Feng, Q., Liu, J., Li, X., Chen, Q., Sun, J., Shi, X., Ding, B., Yu, H., Li, Y., & Jiang, X. (2016) · Small · doi:10.1002/smll.201603109 · Cited by 72
Few‐Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients
Russier, J., León, V., Orecchioni, M., Hirata, E., Virdis, P., Fozza, C., Sgarrella, F., Cuniberti, G., Prato, M., Vázquez, E., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201700078 · Cited by 71
Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells
Liu, K., Huang, J. X., Liu, J., Klionsky, D. J., Kang, R., & Tang, D. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04974-8 · Cited by 80
“MDR refers to the reaction of cancer cells that are resistant to multiple chemotherapeutic drugs simultaneously after being exposed to one chemotherapeutic drug [56].”
BackgroundBłaszczak, E., Miziak, P. A., Odrzywolski, A., Baran, M. T., Gumbarewicz, E., & Stepulak, A. (2025) · Cancers · doi:10.3390/cancers17020228 · Cited by 82
“One mechanism of multidrug resistance involves the enhanced removal of drugs from cancer cells, a process driven by ATP-binding cassette (ABC) transporters [205].”
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.